Study S001320

Leveraging Semaglutide for Preservation of Beta Cell Function and Restoration of Alpha Cell Function

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07430332
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: NOT_YET_RECRUITING
Enrollment: 15
Start: 2027-09-01
Primary completion: 2029-06-01
Lead sponsor: Children's Hospital Medical Center, Cincinnati
Conditions: Stage 1 Diabetes Mellitus, Type 1
Interventions: DRUG:Semaglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

C-peptide area under the curve [12 months]
C-peptide area under the curve (AUC) [12 months]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0008265	Liraglutide protects β-cells in novel human islet spheroid models of type 1 diabetes. Yesildag B, Clinical immunology (Orlando, Fla.)	2022	Other	PMID 36084852 DOI	registry reference BACKGROUND:36084852
R0023832	Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. von Herrath M, The lancet. Diabetes & endocrinology	2021	Randomized trial	PMID 33662334 DOI	registry reference BACKGROUND:33662334